

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 604 662 A8

(12)

CORRECTED EUROPEAN PATENT APPLICATION

Note: Bibliography reflects the latest situation

(15) Correction information:

Corrected version no 1 (W1 A1)**INID code(s) 72**

(48) Corrigendum issued on:

12.04.2006 Bulletin 2006/15

(43) Date of publication:

14.12.2005 Bulletin 2005/50(21) Application number: **04013510.5**(22) Date of filing: **08.06.2004**

(84) Designated Contracting States:

**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PL PT RO SE SI SK TR**

Designated Extension States:

AL HR LT LV MK(71) Applicant: **Santhera Pharmaceuticals****(Deutschland)****Aktiengesellschaft****69120 Heidelberg (DE)**

(72) Inventors:


- **Edwards, Paul John**
69115 Heidelberg (DE)
- **Cerezo-Galvez, Silvia**
42287 Wuppertal (DE)
- **Feurer, Achim**
69259 Wilhelmsfeld (DE)

(51) Int Cl.:

A61K 31/401 ^(2000.01)**A61K 31/472** ^(2000.01)**C07D 207/16** ^(1985.01)**C07D 207/08** ^(1985.01)**C07D 217/14** ^(1985.01)**C07D 241/04** ^(1985.01)**A61K 31/40** ^(1985.01)**A61K 31/495** ^(1985.01)**C07D 207/09** ^(1985.01)**C07D 217/26** ^(1985.01)**C07D 217/16** ^(1985.01)**A61P 3/10** ^(2000.01)• **Matassa, Victor Giulio****69493 Hirschberg (DE)**• **Nordhoff, Sonja****69198 Schrisheim (DE)**• **Hill, Oliver****69239 Neckarsteinach (DE)**• **Thiemann, Meinolf****69121 Heidelberg (DE)**• **Lopez-Canet, Meritxell****69123 Heidelberg (DE)**(74) Representative: **Goldbach, Klara et al****Grünecker, Kinkeldey, Stockmair &****Schwanhäusser****Anwaltssozietät****Maximilianstrasse 58****80538 München (DE)**

(54) **1- γ -(3R)-Amino-4-(2-fluoro-phenyl)-butyl]-pyrrolidine-(2R)-carboxylic acid benzyl amine derivatives and related compounds as dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes mellitus**

(57) The invention relates to compounds of formula (I)



wherein R¹⁻⁹, Z, n, X, A, and R^b have the meaning as cited in the description and the claims. Said compounds are useful as DPP-IV inhibitors. The invention also relates to the preparation of such compounds as well as the production and use thereof as medicament for the treatment of type 2 diabetes mellitus, obesity and lipid disorders.

EP 1 604 662 A8